



Article scientifique

Article

2022

Accepted version

Open Access

This is an author manuscript post-peer-reviewing (accepted version) of the original publication. The layout of the published version may differ .

---

## Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database

---

Iudici, Michele; Mongin, Denis; Siegert, Elise; Carreira, Patricia E; Distler, Jörg; Henes, Jörg; Zanatta, Elisabetta; Hachulla, Eric; De Luca, Giacomo; Müller, Carolina de Souza; Santiago, Tânia; Tandaipan, José-Luis; Bianchi, Breno Valdetaro; De Santis, Maria [and 4 more]

### How to cite

IUDICI, Michele et al. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database. In: Rheumatology, 2022, p. keac533. doi: 10.1093/rheumatology/keac533

This publication URL: <https://archive-ouverte.unige.ch/unige:164385>

Publication DOI: [10.1093/rheumatology/keac533](https://doi.org/10.1093/rheumatology/keac533)

---

## Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database.

Michele Iudici<sup>1</sup>, Denis Mongin<sup>1</sup>, Elise Siegert<sup>2</sup>, Patricia E. Carreira<sup>3</sup>, Jörg Distler<sup>4</sup>, Jörg Henes<sup>5</sup>, Elisabetta Zanatta<sup>6</sup>, Eric Hachulla<sup>7</sup>, Giacomo De Luca<sup>8</sup>, Carolina de Souza Müller<sup>9</sup>, Tânia Santiago<sup>10</sup>, José-Luis Tandaipan<sup>11</sup>, Breno Valdetaro Bianchi<sup>12</sup>, Maria De Santis<sup>13, 14</sup>, Anna-Maria Hoffmann-Vold<sup>15</sup>, Armando Gabrielli<sup>16</sup>, Oliver Distler<sup>17</sup>, Delphine Sophie Courvoisier<sup>1</sup>; on behalf of EUSTAR collaborators\*.

### Affiliations

<sup>1</sup> Rheumatology Unit, Geneva University Hospitals and University of Geneva, Geneva, Switzerland

<sup>2</sup> Department of Rheumatology, Charité University Hospital, Berlin, Germany

<sup>3</sup> Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain

<sup>4</sup> Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany

<sup>5</sup> University Hospital Tuebingen, Center for interdisciplinary rheumatology, immunology and autoimmune diseases (INDIRA), Tuebingen, Germany

<sup>6</sup> Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy

<sup>7</sup> Department of Internal Medicine and Clinical immunology, Referral Centre for Rare Systemic Auto-immune Diseases North and North-West of France, University of Lille, Inserm, CHU Lille, U1286 – INFINITE, University of Lille, Lille, France

<sup>8</sup> Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), San Raffaele Hospital - Vita-Salute San Raffaele University, Milan, Italy

<sup>9</sup> Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil

<sup>10</sup> Rheumatology Department, Hospitais da Universidade Coimbra, Coimbra, Portugal

<sup>11</sup> Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

<sup>12</sup> Department of Rheumatology, Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil

<sup>13</sup> Rheumatology and Clinical Immunology, Humanitas University, Pieve Emanuele; IRCCS-Humanitas Clinical and Research Center, Rozzano (MI), Italy

<sup>14</sup> Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy

<sup>15</sup> Department of Rheumatology, Rikshospitalet University Hospital, Oslo, Norway

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com

<sup>16</sup> Clinica Medica, Università Politecnica delle Marche & Azienda Ospedali Riuniti, Ancona, Italy

<sup>17</sup> Department of Rheumatology, University Hospital Zürich, Zürich, Switzerland

### Corresponding author:

Michele Iudici, MD, PhD, MPH, Rheumatology Unit, Department of Medicine, Geneva University Hospitals, Switzerland. Tel. +41 0223723520; Fax. +41 0223723535

**email.** michele.iudici@hcuge.ch

---

### Abstract

**Objectives.** To estimate the long-term exposure to glucocorticoids (GC), the factors associated with, and the variations in prescribing practices over time and across recruiting countries.

**Methods.** We included patients with systemic sclerosis (SSc) having a visit in the EUSTAR database from January 2013 onward. We analyzed the prevalence and the main features of GC users, the exposure to GC over time, and the respective dosages. Multivariable linear regression analysis identified factors associated with GC intake duration. Time trends, and variations in GC utilization across recruiting countries were explored. Missing data were imputed using multiple imputation with chained equations.

**Results.** The 9819 patients included were mostly females (85%), lcSSc (73%), median age 58 years. At baseline, 34% of patients (n = 2769/8109) (48% dcSSc vs. 29% lcSSc) were on GC, median dose 7.5 mg/day. GC users were more frequently males, dcSSc, anti-Sci70 positive, with a more severe disease. On average, GC users spent 25% of their follow-up time (median 33.2 months) on GC, with no significant between-subsets difference. Notably, 33% (n= 971/2959) and 22% (n= 647/2959) of patients followed-up for >1 year, had received GC for >6 and >12 months, respectively. In multivariable analysis, patient and disease's characteristics poorly explained the variability of GC exposure (adjusted-R<sup>2</sup> = 0.06, P<0.001). GC utilization varied within and across countries, and gradually decreased over time (36% in 2013 vs. 23% in 2018).

1  
2  
3  
4  
5 **Conclusions.** GC are widely and long-term prescribed in SSc, with significant between-  
6 and within-country(ies) differences. A gradual decrease in their utilization is observed.  
7  
8

9 **Keywords.** systemic sclerosis, glucocorticoids, epidemiology  
10  
11

### 12 **Key messages**

- 13  
14  
15  
16     ▪ Glucocorticoids are widely and long-term prescribed in SSc.
- 17  
18  
19  
20     ▪ Glucocorticoids users spent 25% of their follow-up time on these agents.
- 21  
22  
23  
24     ▪ Glucocorticoids utilization is variable within and across countries, and has gradually  
25 decreased over time.  
26  
27  
28  
29

### 30 **Introduction**

31  
32  
33  
34 Although glucocorticoids are largely prescribed in rheumatology for their anti-inflammatory  
35 and disease-modifying action, their role in systemic sclerosis (SSc) is not well established  
36 (1, 2), along with the magnitude of their use in daily care.  
37  
38

39  
40 The rationale for prescribing glucocorticoids comes from the evidence that SSc patients  
41 with early disease present an inflammatory component that can theoretically respond to  
42 steroids (3, 4). Perivascular and tissue inflammatory infiltrates consisting of mononuclear  
43 cells and mainly CD4+ lymphocytes are observed in the skin of early diffuse SSc (5, 6).  
44 Moreover, corticosteroids can decrease vascular leak, and the expression of adhesion  
45 molecules on endothelial cells (7), mechanisms involved in the early phase of SSc  
46 pathogenesis. Glucocorticoids are also prescribed to control symptoms. Experience  
47 accumulated in clinical setting suggests that they are useful to resolve musculoskeletal  
48 inflammatory manifestations, and SSc patients receiving corticosteroids often report  
49 improvement of itchiness, fatigue and appetite (1, 2).  
50  
51  
52

53  
54 However, the use of glucocorticoids remains controversial in SSc because of the lack of  
55 solid evidence demonstrating their anti-fibrotic efficacy when administered alone or in  
56  
57  
58  
59

1  
2  
3 combination with other immunosuppressive drugs. Additionally, important arguments  
4 against their use are the established association with scleroderma renal crisis and  
5 additional, SSc-independent, general adverse events (1, 8). Possible harmful effects of  
6 glucocorticoids include the inhibition of prostaglandins and the amplification of responses  
7 to vasoconstrictive substances like catecholamines (1-7). These actions could potentially  
8 be dangerous in SSc, in which vascular damage can result in Raynaud's phenomenon,  
9 digital ulcers, pulmonary hypertension and scleroderma renal crisis (1-7).  
10  
11  
12  
13  
14

15  
16 Despite these limitations, it seems that use of especially low dose glucocorticoids is  
17 widespread in SSc. Data from cross-sectional studies (9-12) and physician's survey (13)  
18 suggest that up to one-third of limited cutaneous SSc (lcSSc) and up to half diffuse  
19 cutaneous SSc (dcSSc) patients are on corticosteroids at a given time point. However,  
20 differently from other systemic rheumatic diseases, no study has investigated the  
21 utilization of long-term glucocorticoids in SSc. Estimating glucocorticoids exposure, and  
22 understanding the main features associated with their long-term use, is pivotal to achieve  
23 a better and more reasoned prescription, avoid related harms, and identify potential  
24 targets for improvement of quality management.  
25  
26  
27  
28  
29  
30

31  
32 Herein, using data from a large international database, we have estimated to what extent  
33 SSc patients are exposed to glucocorticoids over time, identified the main features of  
34 patients receiving long-term glucocorticoids, and explored variations in prescribing  
35 patterns across countries and over time.  
36  
37  
38  
39

## 40 **Methods**

### 41 EUSTAR database, inclusion criteria and ethics

42  
43 This study used prospectively collected data from the EUSTAR database. The structure  
44 of the EUSTAR database and minimum essential dataset have been described previously  
45 (11, 14). A set of demographics, clinical, imaging, and treatment data are collected at least  
46 yearly for each patient. We included all patients having at least one visit from January 1<sup>st</sup>,  
47 2013 to May, 17th 2019, and available data on glucocorticoids in at least one observation.  
48 The EUSTAR database collects at each visit information on the use and dose of oral  
49 glucocorticoids, expressed as daily dose (milligrams) of prednisone-equivalent.  
50  
51 Local ethic committee permission for each EUSTAR centre and informed consent, where  
52 appropriate according to local ethic regulations, were obtained prior to EUSTAR  
53 enrolment.  
54  
55  
56  
57  
58  
59  
60

### Prevalence of glucocorticoids at study entry, time-trends, and exposure over time

For each patient, we calculated the prevalence of any glucocorticoids use at study entry and the respective dosages. In order to study temporal trends, a cross-sectional analysis evaluating the yearly prevalence of glucocorticoids users was performed between 2013, 1<sup>st</sup> January, (when glucocorticoids use and dose started to be documented), and 17<sup>th</sup> May 2019). The annual prevalence of glucocorticoids use was defined as the proportion of users per 100 individuals for the corresponding year.

For every patient, we identified episode(s) of glucocorticoids use over the entire follow-up. Several treatment episodes from a single patient could have been included. The duration of each episode was the time between two consecutive visits if glucocorticoids were prescribed at both visits. If prescribed at a given visit, but discontinued to the following one, the time spent on glucocorticoids for this treatment episode was considered as half of the time elapsed between the two observations, to account for potential between-visit tapering. Where information was lacking, we carried forward the glucocorticoids status (i.e. 'user' or 'nonuser') of the most recent available visit. In the case of patients on these drugs at the last observation, we added 6-month to the total time spent on glucocorticoids to account for potential tapering of the drug. Time spent on glucocorticoids was then calculated by summing each duration of treatment episode since study entry, and was expressed in months. For patients with no available information on corticosteroids use at baseline, the total follow-up time was calculated from the date of the first visit with available information on glucocorticoids onward, and adding 6-month to total follow-up time. Time spent on glucocorticoids was then normalised by the overall follow-up time, to obtain, for each patient, the percentage of time spent on glucocorticoids.

### Subgroup analyses

Prevalence of glucocorticoid utilization at study entry, time-trends, time spent and proportion of time spent on glucocorticoids, were also evaluated in the subgroup of patients with an early (< 3 years) disease duration, and in patients with limited cutaneous and diffuse cutaneous subset. We also showed the proportion of users at baseline and the median proportion of time spent on glucocorticoids across main recruiting countries (those including more than 100 patients).

### Statistical analysis

For categorical variables, data were presented as frequencies and percentages. Continuous variables were expressed as median [range, interquartile range]. The annual prevalence of glucocorticoids use was defined as the yearly proportion of glucocorticoids

1  
2  
3 users/100 patients. For glucocorticoids users, the association between the median  
4 proportion of time spent on glucocorticoids per country and the median proportion of time  
5 spent on immunosuppressants per country was estimated by Spearman correlation.

6  
7  
8 Factors associated with the proportion of time spent on glucocorticoids were determined  
9 based on expert knowledge, and the association was evaluated using multivariable linear  
10 regression model using age, sex, time from first non-Raynaud, SSc subset, current digital  
11 ulcers, puffy fingers, modified Rodnan skin score, worsening of skin, worsening of  
12 cardiopulmonary, worsening of vascular, joint synovitis, tendon friction rubs, pericardial  
13 effusion, anti-Scl70 positivity, forced vital capacity (FVC), diffusing lung capacity for  
14 carbon monoxide (DLCO), presence of interstitial lung disease, creatine kinase elevation,  
15 C-reactive protein.

16  
17  
18 Missing data were imputed with multiple imputation (MI) using the R package MICE and  
19 the predictive mean matching algorithm. For the imputation model, all the above variables,  
20 except age and gender, were used.

21  
22  
23 A P value < 0.05 was considered statistically significant. Analyses were performed using  
24 R 4.1 statistical software (R Development Core Team, Vienna, Austria).

## 25 26 27 28 29 30 **Results**

### 31 Baseline characteristics, prevalence and factors associated with glucocorticoids use at study 32 entry

33  
34 We studied 9819 of 9989 patients with available data on glucocorticoids over time, of whom  
35 8109 (82%) had information on baseline glucocorticoids use.

36  
37  
38 The 9819 patients included were mostly females (85%), lcSSc (73%), with a median age of 58  
39 years [IQR 48 - 67] and median disease duration from the first non-Raynaud's of 8 years [IQR  
40 3.3 - 14.4]. Less than one tenth (n = 724; 7%), and about one-fifth (n = 1896; 19%) of patients  
41 had <1- and <3- year disease duration, respectively. The main characteristics of the disease  
42 at baseline are summarized in Table 1.

43  
44  
45 Of the 8109 patients with available data on glucocorticoids use at study entry, 2769 (34%)  
46 were considered 'users' at median daily dose of 7.5 mg [IQR 7.5 - 15], with higher figures for  
47 dc- compared to lcSSc patients (966/1991, 48% vs. 1645/5610, 29%; P < 0.001)(Table 1). A  
48 minority of patients had prescribed >15 mg/day (n = 146; 2%) prednisone equivalent. On  
49 average, patients receiving glucocorticoids at baseline were more frequently males, dcSSc,  
50 anti-Scl70 positive, reported more commonly a worsening of skin, cardiopulmonary, vascular  
51 conditions, had an overall more active disease, more joint synovitis, pericardial effusion, higher  
52 C-reactive protein, and worse FVC and DLCO values (Table 1). Patients treated with >15  
53 mg/day vs those receiving ≤ 15 mg/day of prednisone equivalent were more frequently males,  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 dcSSc, had a shorter disease duration, and a higher prevalence of worsening of skin and  
4 respiratory symptoms, lower respiratory volumes, creatine kinase elevation, and an overall  
5 higher disease activity (Supplementary Table S1, available at *Rheumatology* online). In the  
6 whole sample, glucocorticoids were in most of cases (64%) associated with parallel use of an  
7 immunosuppressive drug, mainly methotrexate (29%), cyclophosphamide (21%),  
8 mycophenolate mofetil (21%), azathioprine (17%), rituximab (6%).

9  
10  
11 In the subgroup of patients with an early disease duration (< 3 years from first non-Raynaud's  
12 onset) (n = 1896), the prevalence of users was in line with that observed in the entire sample  
13 (51% for dcSSc vs. 30% for lcSSc, P < 0.001), but the proportion of diffuse patients receiving  
14 glucocorticoids in combination with immunosuppressors raised to 80%.

### 15 16 17 Exposure over time to glucocorticoids

18  
19  
20 During a median follow-up of 33.2 months [IQR 13.1 - 62.6], 3775 (38%) patients (52.3%  
21 dcSSc, n = 1308/2498; 33% lcSSc, n = 2240/6697; P < 0.0001) had received steroids at least  
22 once, with a median dose of 5 mg/day. Twenty-one percent of patients who had received  
23 glucocorticoids experienced at least one episode of arthritis during the follow-up, 12% at least  
24 one episode of myositis and/or increased creatine kinase values, and 30% either arthritis or  
25 myositis and/or increased creatine kinase values.

26  
27  
28 The median time spent on glucocorticoids was 6 months [IQR 6-9, range 1 - 96]. On average,  
29 they spent 25% [IQR 12 - 58] of their follow-up time on glucocorticoids. For patients who were  
30 followed-up for > 1 year (n = 2959), 971 (33%) and 647 (22%) had received glucocorticoids for  
31 more than 6 and 12 months, respectively (Figure 1). Exposure to glucocorticoids was  
32 significantly longer for males (median 28% [IQR 13 - 71] vs. 25% [IQR 12 - 53], P < 0.01), but  
33 comparable between limited and diffuse subsets. Accordingly, the number of patients on  
34 glucocorticoids for more than one-third (503/1308 [38%] dcSSc vs. 862/2240 [38%] lcSSc; P  
35 = 0.987) or more than half (365/1308 [28%] dcSSc vs. 577/2240 [26%] lcSSc; P = 0.162) of  
36 the follow-up time was also comparable between the subsets. The analysis of patients with an  
37 early disease (time from the first non-Raynaud's onset < 3 years), led to similar results, both  
38 in terms of proportion time spent on glucocorticoids (median 27% [IQR 14-49] of follow-up  
39 time), or for the rate of SSc patients receiving glucocorticoids for more than one-third (132/336  
40 [39%] dcSSc vs. 147/418 [35%] lcSSc; P = 0.24), or more than half (94/336 [28%] dcSSc vs.  
41 114/418 [27%] lcSSc; P = 0.83) of the follow-up time.

42  
43  
44 The longitudinal analysis of glucocorticoids prescription showed that they were used in  
45 combination with an immunosuppressive drug in 2462/4356 (57%) of the visits, mainly with  
46 methotrexate (24%), mycophenolate mofetil (18%), cyclophosphamide (16%), azathioprine  
47 (14%) and rituximab (6%).

Multivariable linear regression showed that the proportion of time spent on corticosteroids was positively associated with age, male sex, worsening of cardiopulmonary manifestations, synovitis, tendon friction rubs, pericardial effusion, lower FVC or DLCO, lung fibrosis at high-resolution computed tomography, increased creatine kinase or C-reactive protein, and negatively associated with the limited subset and the mRSS (adjusted  $R^2 = 0.06$ ,  $P > 0.0001$ ). The results of linear regression in the whole sample, and in the subgroup of patients with early disease are shown in Table 2.

#### Temporal trends of glucocorticoids use

The annual proportion of glucocorticoids users gradually decreased between 2013 and 2018 in the overall sample of patients (36% in 2013 vs. 23% in 2018), both in those with lcSSc (23% in 2013 to 14% in 2018), or dcSSc (36% in 2013 to 23% in 2018). To adjust for disease severity, the same analysis performed in patients with an early disease duration confirmed the observed trend, with the rate of dcSSc glucocorticoids users falling from about 60% in 2013 to less than 40% in 2018. Figure 2 shows the temporal trend of glucocorticoids use in the whole sample and in early SSc patients.

#### Prescribing practices according to countries

The baseline proportion of glucocorticoids users (in the whole sample and for each SSc subset) across the main recruiting countries was highly heterogeneous, with the highest figures recorded in Russia, Turkey, and Poland, the lowest in Denmark and Belgium (Figure 1). In most countries, glucocorticoids have been prescribed in more than 50% of dcSSc patients (Figure 1).

The median proportion of time spent on glucocorticoids also greatly varied across countries (Figure 3). We found a strong correlation between the median proportion of time spent on glucocorticoids and the median proportion of time spent on immunosuppressants per country among patients treated with glucocorticoids ( $\rho 0.71$  [95%CI 0.30 - 0.90],  $P = 0.001$ ) (Supplementary Figure S1, available at *Rheumatology* online). The wide range of time spent on glucocorticoids within each country mirrors the high variability in prescribing patterns across countries.

### **Discussion**

We have shown that glucocorticoids were commonly prescribed in SSc, mainly to patients with a more severe condition or presenting signs or symptoms of an active inflammatory disease. One-third of glucocorticoid-treated patients had an active musculoskeletal inflammatory condition over their disease course. Although more dcSSc patients received glucocorticoids,

1  
2  
3 the duration of treatment (on average a quarter of follow-up time) was similar in the two  
4 subsets. We observed a huge heterogeneity of glucocorticoids prescription across and within  
5 countries, and the mean time spent on these agents was poorly explained by patient's features.  
6 Interestingly, these drugs are being gradually less prescribed. Doses higher than 15 mg/day  
7 were rarely given, mainly to patients with a high disease activity and with lung and skin  
8 worsening disease.  
9  
10  
11  
12

13  
14 Our cross-sectional analysis revealed that, at study entry, about one third of lcSSc and half of  
15 dcSSc patients were current corticosteroid users, with similar figures in both the whole sample  
16 and in the subgroup of incident patients. This finding, consistent with the results of a meta-  
17 analysis from national and international SSc registries and cohorts (10), confirms a large use  
18 of these drugs in SSc, irrespective from disease duration (our main analysis focused on  
19 patients with a median disease duration of about 8 years), and in spite of the absence of  
20 evidence about their efficacy (1, 13, 15). In daily practice, by analogy with other inflammatory  
21 autoimmune diseases, glucocorticoids are prescribed in SSc to obtain symptoms relief or to  
22 treat overt active inflammatory manifestations (1). They are also delivered in combination with  
23 immunosuppressive drugs for interstitial lung disease or diffuse skin fibrosis (1, 13, 15), even  
24 if their utility is not proven. The results of two randomized controlled trials investigating the  
25 efficacy of glucocorticoids in early diffuse disease (16, 17), will hopefully better drive their use  
26 in this subgroup of patients in next years. As far as interstitial lung disease, corticosteroids at  
27 a dose  $\leq 10$  mg per day are generally among the permitted concomitant medications in  
28 randomized controlled trials, but no study has specifically demonstrated any benefit of these  
29 agents for this indication. A recent European consensus statement, recommended against  
30 glucocorticoids monotherapy for the treatment of interstitial lung disease (18).  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 Even at low doses, long-term glucocorticoid use is associated with increased risk of infection,  
44 osteoporosis, cataract, cardiovascular events (19, 20), and tapering glucocorticoids as rapidly  
45 as clinically feasible is recommended in most systemic autoimmune diseases. Nevertheless,  
46 a glucocorticoid-free status was not reached in our sample for a considerable proportion of  
47 SSc patients. Indeed, we observed that nearly 1 of 3 treated patients followed for at least 1  
48 year continued to receive  $\geq 5$  mg/day of corticosteroids for more than 6 months, and about 1  
49 of 4 for more than 1 year. The reasons accounting for long-term glucocorticoids exposure in  
50 SSc are various and difficult to be completely understood. Physician's beliefs about the utility  
51 of long-term exposure to corticosteroids (21), failure to achieve discontinuation (22, 23), or the  
52 poor knowledge about the detrimental effects of long-term low dose corticosteroids use (24),  
53 could at least in part explain such observation.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 Glucocorticoids prescription hugely varied across and within countries in our study, and the  
6 variability of glucocorticoids exposure was poorly explained by patient's related information.  
7 The strong correlation found between the extent of glucocorticoids use and that of  
8 immunosuppressive drugs weakens the hypothesis that the larger use of glucocorticoids in  
9 some countries could be justified by the unavailability of drugs with steroid-sparing effect.  
10 Conversely, it could reflect regional differences in management practices (i.e. physicians more  
11 prone to prescribe glucocorticoids and immunosuppressive drugs in some countries). A  
12 comprehensive analysis of the relationship between the prescription of glucocorticoids,  
13 immunosuppressive agents, and disease severity, would help to better understand differences  
14 in SSc management. This deserves a dedicated study and is beyond the aim of this paper.  
15 The high variability in glucocorticoids prescribing practices within countries also suggests that  
16 the lack of agreement among physicians (25) might be the main driver. Even if we cannot  
17 demonstrate this aspect by the analysis of our data, various studies have clearly shown that  
18 there is no consensus on how, to whom, and for how long glucocorticoids should be prescribed  
19 in SSc (12, 25-27). In the European Scleroderma Observational Study (ESOS) just about half  
20 of early diffuse patients received or had received glucocorticoids (12). Discrepancy in  
21 glucocorticoids use was highlighted in a survey conducted among experts from the  
22 Scleroderma Clinical Trials Consortium and from the Canadian Scleroderma Research (25).  
23 The observation that patient's characteristics explained only about 6% of the variability of  
24 glucocorticoids exposure in our multivariable model, further support this hypothesis. That said,  
25 we should acknowledge that in spite of a huge variability in prescribing practices, we found  
26 high consistency about the doses used, given that only a very small proportion of patients with  
27 a very active and severe disease had received more than 15 mg per day of prednisone  
28 equivalent. We remind that the risk of scleroderma renal crisis should always be kept in mind  
29 when prescribing prednisone equivalent higher than 15 mg per day to SSc patients.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Interestingly, glucocorticoids were less prescribed over time. This seems to be unrelated to  
47 the inclusion of patients with a milder disease these last years, since the same trends was also  
48 shown for those with a severe disease (early dcSSc). Reasons for this finding can include a  
49 better knowledge about the lack of proofs demonstrating the utility of these agents for  
50 preventing lung or skin fibrosis worsening (1, 2, 15, 28). We can also hypothesize that the  
51 growing awareness about the harms related to glucocorticoids chronic use, could represent a  
52 contributing factor. Actually, more attention is being paid over the last few years to the side  
53 effects associated with long-term glucocorticoids exposure, even if used at low dosages (29-  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 36), and steroid-free strategies are increasingly tested for systemic autoimmune diseases (37-  
4 39).  
5  
6  
7

8 This study has some limitations. Due to the lack of available information, we were not able to  
9 explore the main indications for glucocorticoids prescription or discontinuation. This could have  
10 enabled us to better understand if long-term use is driven more by the need to control  
11 symptoms, by physician's beliefs about their potential effectiveness to slow down fibrosis  
12 accumulation, or by other reasons. Moreover, we could not appraise the potential SSc-  
13 (un)related consequences of the long-term intake of corticosteroids since many of these  
14 complications need to be investigated in a longer time span. Information bias is an issue, for  
15 two reasons. First, misclassification of glucocorticoids use is possible, since some patients  
16 could have filled a prescription only for short-term use in case of flares, or may have received  
17 these compounds for other reasons. Second, time on glucocorticoids was extrapolated  
18 between visits, and after last visit (by adding 6 months). However, this measurement error  
19 should not lead to systematic bias because it is not likely associated with clinical  
20 characteristics. Finally, our data mirrors the practice observed in the EUSTAR centers, that  
21 could not be representative of the whole picture of glucocorticoids management in a given  
22 country.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 The strengths of this study are the availability of a large sample of patients, coming from  
34 different continents, and reflecting the daily clinical practices across the centres  
35 contributing to the EUSTAR database. Furthermore, we have for the first time  
36 prospectively explored the burden of glucocorticoids intake over time in SSc, topic that is  
37 (and has been) neglected in this disease so far.  
38  
39  
40  
41  
42

43 In conclusion, low-dose oral corticosteroids are widely and long-term prescribed to SSc  
44 patients, mainly to those with a diffuse cutaneous subset. Glucocorticoids prescription is  
45 greatly heterogeneous across centers and countries, and is steadily declining in last years.  
46 Even if relatively few patients received more than 15 mg per day of prednisone, the risk of  
47 scleroderma renal crisis should always be considered for patients receiving this dosage.  
48 Identifying areas of high variability in practice underscores the need for better evidence to drive  
49 corticosteroids prescription and might also be instrumental to suggest potential targets for  
50 quality improvement.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgments.

**EUSTAR collaborators:** Giovanna Cuomo (Naples, Italy), Gianluca Moroncini (Ancona, Italy), Jiri Stork (Prague, Czech Republic), Fiorenzo Iannone (Bari, Italy), Ulrich Walker (Basel, Switzerland), Eugenia Bertoldo (Verona, Italy), Dorota Krasowska (Lublin, Poland), Maria João Salvador (Coimbra, Portugal), Mohammed Tikly (Johannesburg, South Africa), Valeria Ricciari (Rome, Italy), Ami Sha (Baltimore, MD, USA), Ana Maria Gheorghiu (Bucharest, Romania), Cord Sunderkötter (Münster, Germany), Francesca Ingegnoli (Milan, Italy), Luc Mouthon (Paris, France), Vanessa Smith (Gent, Belgium), Francesco Paolo Cantatore (Foggia, Italy), Kilian Eyerich (Munich, Germany), Piotr Wiland (Wroclaw, Poland), Marie Vanthuyne (Brussels, Belgium), Branimir Anic (Zagreb, Croatia), Maria Üprus (Tallin, Estonia), Brigitte Granel (Marseille, France), Alessandra Vacca (Monserrato, Italy), Cristina-Mihaela Tanaseanu (Bucharest, Romania), Paloma García de la Peña Lefebvre (Madrid, Spain), Jean Sibilia (Strasbourg, France), Ira Litinsky (Tel Aviv, Israel), Lesley Ann Saketkoo (New Orleans, LA, USA), Eduardo Kerzberg (Buenos Aires, Argentina), Massimiliano Limonta (Bergamo, Italy), Doron Rimar (Haifa, Israel), Petros Sfikakis (Athens, Greece), Maurizio Cutolo (Genova, Italy), Rosario Foti (Catania, Italy), Srdan Novak (Rijeka, Croatia), Mislav Radic (Split, Croatia), Raffaele Pellerito (Torino, Italy), Carlo Francesco Selmi Rozzano (Milan, Italy), Lidia P. Ananieva (Moscow, Russia), Gabriela Szűcs (Debrecen, Hungary), Carlos de la Puente (Madrid, Spain), Ruxandra Maria Ionescu (Bucharest, Romania), Maria Rosa Pozzi (Monza, Italy), Juan Jose Alegre-Sancho (Valencia, Spain), Kristine Herrmann (Dresden, Germany), Ellen De Langhe (Leuven, Belgium), Sule Yavuz Altunizade (Istanbul, Turkey), Svetlana Agachi (Chisinau, Republic of Moldova), Douglas Veale (Dublin, Ireland), Esthela Loyo (Santiago, Dominican Republic), Mengtao Li (Beijing, China), Edoardo Rosato (Rome, Italy), Britta Maurer (Bern, Switzerland), Iván Castellví (Barcelona, Spain), François Spertini (Lausanne, Switzerland), Kamal Solanki (Hamilton, New Zealand), Nicoletta Del Papa (Milan, Italy), Gerard Espinosa (Barcelona, Spain), László Czirják (Pecs, Hungary), Bernard Coleiro (Balzan, Malta), Dominique Farge Bancel (Paris, France), Raffaele Pellerito (Torino, Italy), Christopher Denton (London, UK), Nemanja Damjanov (Belgrade, Serbia and Montenegro), Vera Ortiz Santamaria Granollers (Barcelona, Spain), Michaela Kohm (Frankfurt am Main, Germany), Bojana Stamenkovic (Niska Banja, Serbia and Montenegro), Yannick Allanore (Paris, France), Paolo Airo' (Brescia, Italy), Alexandra Balbir-Gurman (Haifa, Israel), Marco Matucci Cerinic (Firenze, Italy), Gabriela Riemekasten (Lübeck, Germany), Stefan Heitmann (Stuttgart, Germany), Nicolas Hunzelmann (Köln, Germany), Carlomaurizio Montecucco (Pavia, Italy), Jadranka Morovic-Vergles (Zagreb, Croatia), Camillo Ribi (Lausanne, Switzerland).

## Other Acknowledgements

This work was presented in form of abstract at the EULAR Congress 2022, in Copenhagen (POS0874).

**Authors contribution.** All the authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Michele Iudici had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

*Study conception and design.* Iudici, Courvoisier. *Acquisition of data.* Iudici, Siegert, Carreira, Distler, Henes, Zanatta, Hachulla, De Luca, de Souza Müller, Santiago, Tandaipan, Valdetaro Bianchi, De Santis, Hoffmann-Vold, Gabrielli, Distler, Courvoisier. *Analysis and interpretation of data.* Iudici, Mongin, Siegert, Carreira, Distler, Henes, Zanatta, Hachulla, De Luca, de Souza Müller, Santiago, Tandaipan, Valdetaro Bianchi, De Santis, Hoffmann-Vold, Gabrielli, Distler, Courvoisier

## Conflict of interests

Michele Iudici: speaking fee from Boehringer Ingelheim; Denis Mongin: None declared; Elise Siegert: None declared; Patricia Carreira: None declared; Jörg H.W. Distler: None declared; Jörg Henes: speaking fees from Roche/Chugai, Janssen, Neovii and Boehringer-Ingelheim; Elisabetta Zanatta: None declared; Eric Hachulla: speaking fees from Johnson & Johnson, GSK, Roche-Chugai; and research funding from CSL Behring, GSK, Roche-Chugai and Johnson & Johnson., Consultant of: consulting fees/meeting fees from Johnson & Johnson, Boehringer Ingelheim, Bayer, GSK, Roche-Chugai, Sanofi-Genzyme; Giacomo De Luca: None declared; Carolina Souza Muller: speaking fees for Janssen and Boehringer-Ingelheim; Maria Joao Salvador: None declared; Jose Luis Tandaipan: None declared; Breno Valdetaro Bianchi: None declared; Maria De Santis: None declared; Anna-Maria Hoffmann-Vold: research funding, consulting fees, or other remuneration from Actelion, Boehringer Ingelheim, Roche, Bayer, Merck Sharp & Dohme, ARXX therapeutics, Lilly, and Medscape. Armando Gabrielli: None declared; Oliver Distler: has/had consultancy relationship with and/or has received research funding from or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three years: Abbvie, Acceleron, Amgen, AnaMar, Arxx, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos NV, Glenmark, GSK, Horizon (Curzion), Inventiva, iQvia,

Italfarmaco, Kymera, Medac, Medscape, Mitsubishi Tanabe, MSD, Novartis, Pfizer, Roche, Roivant, Sanofi, Serodapharm, Topadur, Target Bioscience and UCB. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143). Delphine Courvoisier: None declared

## Funding

No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

**Data availability statement.** The data that support the findings of this study are available upon reasonable request.

## Tables

**Table 1.** Characteristics of SSc patients included in the study.

Characteristics	Overall sample N=9819	Not on GC N=5340	on GC N=2769	P	Missing data (%)*
Age, median (IQR)	58 (48-67)	58 (48-67)	57 (47-67)	0.253	0
Male sex, n, %	1476 (15)	734 (14)	490 (18)	<0.001	0
Body weight, Kg, median (IQR)	65 (57-75)	65 (57-74)	65 (56-75)	0.983	11
<b>Disease characteristics</b>					
lcSSc subset, n, %	6697 (73)	3965 (80)	1645 (63)	<0.001	6
Disease duration since first non-Raynaud symptom, median (IQR), years	8 (3.3-14.4)	7.5 (3-14)	7.5 (3-14)	0.124	15
mRSS, median (IQR)	5 (2-11)	5 (2-9)	7 (2-14)	<0.001	15
Raynaud's phenomenon, n, %	9086 (95)	5043 (96)	2602 (96)	0.664	3

Intestinal symptoms, n, %	2325 (24)	1218 (23)	703 (26)	0.013	3
Puffy fingers, current, n, %	3411 (42)	1966 (43)	966 (41)	0.025	17
Current digital ulcers, n, %	1113 (14)	620 (12)	436 (17)	<0.001	18
Joint synovitis, n, %	1084 (11.6)	392 (8)	538 (21)	<0.001	4
Worsening of finger vascularization within the last month, n, %	1773 (20)	971 (20)	603 (24)	<0.001	9
Worsening of skin within the last month, n, %	1208 (14)	629 (13)	456 (18)	<0.001	9
Worsening of cardiopulmonary manifestation within the last month, n, %	1204 (11)	449 (9)	445 (17)	<0.001	8
Pericardial effusion, n, %	432 (6)	192 (5)	187 (9)	<0.001	28
Renal crisis, ever, n, %	142 (2)	63 (1)	55 (2)	0.006	2
Disease activity score 2001, score, median (IQR)	3 (2-5)	2 (1-5)	4 (2-6)	<0.001	0.5
DLCO/SB, median (IQR), % of predicted	69 (56-81)	71 (59-83)	64 (50-77)	<0.001	26
FVC, median (IQR), % of predicted	97 (81-110)	100 (85-113)	90 (74-105)	<0.001	21
Fibrosis at lung HRCT, n, %	2519 (45)	1048 (36)	1123 (60)	<0.001	43
<b>Laboratory parameters</b>					
Creatine kinase elevation (>3 ULN), n, %	667 (8)	330 (8)	274 (12)	<0.001	19
CRP elevation, n, %	1991 (23)	924 (19)	822 (33)	<0.001	28
Anti-centromere positive, n, %	3543 (42)	2366 (50)	646 (27)	<0.001	14
Anti-topoisomerase I positive, n, %	2799 (33)	1264 (27)	1067 (42)	<0.001	13
Anti-RNA polymerase III, n, %	374 (7)	226 (7)	105 (7)	0.854	43
<b>Treatment</b>					
Cyclophosphamide, n, %	843 (10)	256 (5)	566 (21)	<0.001	15
Methotrexate, n, %	1479 (18)	670 (13)	780 (29)	<0.001	16
Mycophenolate mofetil, n, %	990 (12)	406 (8)	563 (21)	<0.001	15
Azathioprine, n, %	763 (9)	282 (5)	462 (17)	<0.001	16
Rituximab, n, %	252 (3)	80 (1.5)	161 (6)	<0.001	0

**GC**, glucocorticoids; **IQR**, interquartile range; **mRSS**, modified Rodnan skin score; **SD**, standard deviation; **DLCO/SB**. Single breath diffusing capacity for carbon monoxide; **FVC**. Forced vital capacity; **HRCT**, High-resolution computed tomography; **ULN**, upper limit of normal. \* Rate of missing data for patients with available data on glucocorticoids.

**Table 2.** Association of demographic and disease-related factors with the proportion time spent on glucocorticoids.

	Whole series N = 8109		Early SSc patients N =	
	Coef (95%CI)	P value	Coef (95%CI)	P value
<b>Demographics</b>				
Age	0.05 (0.01; 0.09)	<0.001	0.05 (-0.01; 0.13)	0.13
Male	2.3 (0.7; 3.9)	0.003	1.5 (-1.1; 4.1)	0.24
<b>Characteristics of disease</b>				
Time from first non-Raynaud	-0.02 (-0.09; 0.05)	0.55	-	-
lcSSc	-3.9 (-6.1; -1.6)	<0.001	-3.5 (-7.0; -0.06)	0.006
Current digital ulcers	-0.2 (-2.8; 2.3)	0.77	0.6 (-3.0; 4.3)	0.71
Puffy fingers	-0.031 (-1.8; 1.2)	0.58	1.3 (-1.0; 3.5)	0.22
mRSS	-0.09 (-0.3; 0.1)	<0.001	-0.07 (-0.3; 0.2)	0.17
Worsening of skin	1.6 (-1.5; 4.7)	0.07	1.8 (-1.4; 5.1)	0.21
Worsening of cardiopulmonary manifestation	5.6 (2.0; 9.3)	<0.001	8.5 (4.2; 12.8)	<0.001
Worsening of vascular manifestations	0.5 (-1.8; 2.9)	0.42	-1.3 (-4.2; 1.6)	0.29
Joint synovitis	8.5 (6.4; 10.5)	<0.001	6.5 (3.3; 9.7)	<0.001
Tendon friction rubs	4.4 (1.4; 7.4)	<0.001	2.7 (-1.7; 7.0)	0.21
Pericardial effusion	2.3 (-0.9; 5.4)	0.03	3.4 (-2.1; 8.8)	0.11
Anti-Scl70 positive	1.1 (-0.6; 2.7)	0.11	0.20 (-0.2; 4.8)	0.62
FVC	-0.01 (-0.1; -0.02)	<0.001	-0.01 (-0.08; 0.05)	0.57
DLCO	-0.04 (-0.1; 0.01)	<0.001	-0.05 (-0.12; 0.02)	0.04
Fibrosis at lung HRCT	4.4 (2.3; 7.0)	<0.001	5.2 (2.2 - 8.2)	<0.001
<b>Laboratory</b>				
Creatine kinase elevation	4.0 (0.9; 7.0)	<0.001	3.6 (-0.4; 7.6)	0.03
C-reactive protein	5.0 (3.0; 7.0)	<0.001	5.1 (2.2; 8.0)	<0.001

**SE.** Standard error; **lcSSc.** Limited cutaneous SSc; **mRSS.** Modified Rodnan skin score; **FVC.** Forced vital capacity; **DLCO.** Diffusing lung capacity for carbon monoxide; **HRCT,** High-resolution computed tomography.

1  
2  
3 **Figure 1.** Proportion of patients followed-up > 1 year who had been treated with  
4 glucocorticoids.  
5  
6

7  
8 Legend. Proportion of patients followed-up > 1 year who had been treated with  
9 glucocorticoids (GC) for less or equal (blue bars) or more (red bars) than 6 months. Data are  
10 shown for the whole dataset and by countries, for diffuse cutaneous (left panel) or limited  
11 cutaneous (right panel) systemic sclerosis patients.  
12  
13  
14  
15  
16  
17  
18  
19

20 **Figure 2.** Yearly prevalence of glucocorticoids users.  
21  
22

23 Legend. Yearly prevalence of glucocorticoids (GC) users in the whole sample of patients  
24 (circles and solid lines), or in patients with a disease duration < 3 year (squares and dashed  
25 lines), according to disease subset.  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 **Figure 3.** Proportion time under glucocorticoids, and time under glucocorticoids for  
36 glucocorticoids users, in main recruiting countries.  
37  
38

39 Legend. GC, glucocorticoids.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Iudici M, van der Goes MC, Valentini G, Bijlsma JW. Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. *Clin Exp Rheumatol* 2013;31:157-65.
2. Blagojevic J, Legendre P, Matucci-Cerinic M, Mouthon L. Is there today a place for corticosteroids in the treatment of scleroderma? *Autoimmun Rev* 2019;18:102403.
3. Hua-Huy T, Dinh-Xuan AT. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis. *Pathol Biol (Paris)* 2015;63:61-8.
4. Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. *Curr Opin Rheumatol* 2009;21:617-22.
5. Roumm AD, Whiteside TL, Medsger TA, Jr., Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. *Arthritis Rheum* 1984;27:645-53.
6. Parel Y, Aurrand-Lions M, Scheja A, Dayer JM, Roosnek E, Chizzolini C. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. *Arthritis Rheum* 2007;56:3459-67.
7. Bruni C, Frech T, Manetti M, Rossi FW, Furst DE, De Paulis A, et al. Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed? *Front Immunol* 2018;9:2045.
8. Steen VD. Scleroderma renal crisis. *Rheum Dis Clin North Am* 2003;29:315-33.
9. Hunzelmann N, Moinzadeh P, Genth E, Krieg T, Lehmacher W, Melchers I, et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. *Arthritis Res Ther* 2009;11:R30.
10. Iudici M, Fasano S, Iacono D, Russo B, Cuomo G, Valentini G. Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. *Clin Rheumatol* 2014;33:153-64.

- 1  
2  
3 11. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al. Update on  
4 the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research  
5 group database. *Ann Rheum Dis* 2012;71:1355-60.
- 6  
7 12. Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, et al. Treatment  
8 outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma  
9 Observational Study (ESOS). *Ann Rheum Dis* 2017;76:1207-18.
- 10  
11 13. Harding S, Khimdas S, Bonner A, Baron M, Pope J. Best practices in scleroderma: an  
12 analysis of practice variability in SSc centres within the Canadian Scleroderma Research  
13 Group (CSRG). *Clin Exp Rheumatol* 2012;30:S38-43.
- 14  
15 14. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al.  
16 Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the  
17 EULAR Scleroderma Trials And Research group database. *Ann Rheum Dis* 2007;66:754-63.
- 18  
19 15. Iudici M. What should clinicians know about the use of glucocorticoids in systemic  
20 sclerosis? *Mod Rheumatol* 2017;27:919-23.
- 21  
22 16. van den Hombergh WMT, Kersten BE, Knaapen-Hans HKA, Thurlings RM, van der  
23 Kraan PM, van den Hoogen FHJ, et al. Hit hard and early: analysing the effects of high-dose  
24 methylprednisolone on nailfold capillary changes and biomarkers in very early systemic  
25 sclerosis: study protocol for a 12-week randomised controlled trial. *Trials* 2018;19:449.
- 26  
27 17. Herrick AL, Griffiths-Jones DJ, Ryder WD, Mason JC, Denton CP. Clinical trial protocol:  
28 PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS). *J Scleroderma Relat*  
29 *Disor* 2021;6:146-53.
- 30  
31 18. Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, et.  
32 al. The identification and management of interstitial lung disease in systemic sclerosis:  
33 evidence-based European consensus statements. *Lancet Rheumatol* 2020;2:e71–83.
- 34  
35 19. Wilson JC, Sarsour K, Gale S, Pethö-Schramm A, Jick SS, Meier CR. Incidence and  
36 Risk of Glucocorticoid-Associated Adverse Effects in Patients With Rheumatoid Arthritis.  
37 *Arthritis Care Res (Hoboken)* 2019;71:498-511.
- 38  
39 20. Black RJ, Hill CL, Lester S, Dixon WG. The Association between Systemic  
40 Glucocorticoid Use and the Risk of Cataract and Glaucoma in Patients with Rheumatoid  
41 Arthritis: A Systematic Review and Meta-Analysis. *PLoS One* 2016;11:e0166468.
- 42  
43 21. Cantrill JA, Dowell J, Roland MO. General practitioners' views on the appropriateness  
44 of their long-term prescribing, *The European Journal of General Practice* 2000;6:5-9.
- 45  
46 22. Iudici M, Vettori S, Russo B, Giacco V, Capocotta D, Valentini G. Outcome of a  
47 glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis. *Clin*  
48 *Rheumatol* 2016;35:1985-91.
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

23. Borresen SW, Klose M, Baslund B, Rasmussen Å K, Hilsted L, Friis-Hansen L, et al. Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. *Eur J Endocrinol* 2017;177:287-95.
24. Cooper V, Metcalf L, Versnel J, Upton J, Walker S, Horne R. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. *NPJ Prim Care Respir Med* 2015;25:15026.
25. Fernández-Codina A, Walker KM, Pope JE. Treatment Algorithms for Systemic Sclerosis According to Experts. *Arthritis Rheumatol* 2018;70:1820-8.
26. Wallace BI, Lin P, Kamdar N, Noureldin M, Hayward R, Fox DA, et al. Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. *Semin Arthritis Rheum* 2020;50:228-36.
27. George MD, Baker JF, Wallace B, Chen L, Wu Q, Xie F, et al. Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids. *Arthritis Care Res (Hoboken)* 2021;73:1597-605.
28. Iudici M, Russo B, Mitidieri M, Cuomo G, Valentini G. Glucocorticoids in systemic sclerosis: patients' beliefs and treatment adherence. *Scand J Rheumatol* 2015;44:229-37.
29. Xie W, Huang H, Li G, Hao Y, Gui Y, Wang Y, et al. Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020. *Ann Rheum Dis*, 2021 Apr 2 [Online ahead of print].
30. George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L, et al. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. *Ann Intern Med* 2020;173:870-8.
31. Xie W, Yang X, Ji L, Zhang Z. Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis. *Semin Arthritis Rheum* 2020;50:598-607.
32. Roubille C, Coffy A, Rincheval N, Dougados M, Flipo RM, Daurès JP, et al. Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. *Rheumatology (Oxford)* 2021;60:3738-46.
33. Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. *Ann Rheum Dis* 2012;71:1128-33.

- 1  
2  
3 34. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer  
4 A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic  
5 and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*  
6 2020;79:685-99.  
7  
8 35. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021  
9 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.  
10 *Arthritis Care Res (Hoboken)* 2021;73:924-39.  
11  
12 36. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019  
13 update of the EULAR recommendations for the management of systemic lupus erythematosus.  
14 *Ann Rheum Dis* 2019;78:736-45.  
15  
16 37. Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the Treatment of ANCA-  
17 Associated Vasculitis. *N Engl J Med* 2021;384:599-609.  
18  
19 38. Killock D. Lupus nephritis: a rituximab-based regimen might enable oral steroid  
20 avoidance in lupus nephritis. *Nat Rev Rheumatol* 2013;9:443.  
21  
22 39. Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, Dougados M,  
23 et al. Continuing versus tapering glucocorticoids after achievement of low disease activity or  
24 remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled  
25 trial. *Lancet* 2020;396:267-76.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Proportion of patient followed-up > 1 year who had been treated with glucocorticoids for less or equal (blue bars) or more (red bars) than 6 months. Data are shown for the whole dataset and by countries, for diffuse cutaneous (left panel) or limited cutaneous (right panel) SSc patients.

88x63mm (600 x 600 DPI)




Figure 2. Yearly prevalence of GC users in the whole sample of patients (circles and solid lines), or in patients with a disease duration < 3 year (squares and dashed lines), according to disease subset.

88x63mm (600 x 600 DPI)




Figure 3. Distribution of the proportion of time under GC, and of the time under GC for GC users, in main recruiting countries.

88x63mm (600 x 600 DPI)